1715 38TH ST, BOULDER, CO
Reports Second Quarter 2026 Financial Results
Amended material disclosure
Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Focus on Cardiovascular Pipeline
Annual Meeting Results: Election of Directors and Auditor Ratification
Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Focus on Cardiovascular Pipeline
Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs
Q2
Q1
FY 2024
Q3
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
Amended Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership